pd 173074 and azd 6244
pd 173074 has been researched along with azd 6244 in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| An, S; Ban, MJ; Byeon, HK; Kee, H; Kim, DH; Kim, JH; Kim, JW; Koh, YW; Yang, J; Yang, YJ | 1 |
Other Studies
2 other study(ies) available for pd 173074 and azd 6244
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Fibroblast growth factor receptor 3-mediated reactivation of ERK signaling promotes head and neck squamous cancer cell insensitivity to MEK inhibition.
Topics: Animals; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Fibroblast Growth Factor 2; Head and Neck Neoplasms; Humans; MAP Kinase Signaling System; Mice; Pyrimidines; Receptor, ErbB-3; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2018 |